Acura Pharmaceuticals, Inc., a specialty pharmaceutical company innovating abuse deterrent drugs, announced today financial results for the three and nine months ended September 30, 2017.. The Company reported a net loss of $2.2 million or $0.12 per diluted share for quarter ended September 30, 2017 compared to a net loss of $2.3 million or $0.19
This discussion and analysis should be read in conjunction with the Company's financial statements and accompanying notes included elsewhere in this Report. Historical operating results are not necessarily indicative of results in future periods. with Oxford Finance LLC, or to obtain a waiver from Oxford Finance LLC for our.
Zug, Switzerland- November 13, 2017- Shire plc, the world's leading biotechnology company in rare diseases, announced today that the Committee for Medicinal Products for Human Use of the European Medicines Agency has issued a positive opinion recommending the granting of marketing authorization for ADYNOVI, an extended half-life recombinant Factor
Innovus Pharmaceuticals, Inc., an emerging commercial-stage pharmaceutical company that delivers safe, innovative and effective over-the-counter medicine and consumer care products to improve men s and women's health and respiratory diseases, today announced that it has entered into an additional agreement with current partner ACON Laboratories,
Ahead of today's trading session, DailyStockTracker.com observes the performance of four major players in this space: AstraZeneca PLC, Impax Laboratories Inc., TherapeuticsMD Inc., and GlaxoSmithKline PLC. Cambridge, the UK headquartered AstraZeneca PLC's stock finished last Friday's session 0.60% lower at $32.91. Additionally, shares of AstraZenec
The House Education and the Workforce subcommittee on Early Childhood, Elementary and Secondary Education, and subcommittee on Higher Education and Workforce Development issued the following testimony by Baltimore City Health Commissioner Leana Wen, at a hearing entitled "Close to Home: How Opioids are Impacting Communities":. "Subcommittee Chairm
This morning, DailyStockTracker.com takes a closer look at four equities in this space to see how they have fared over the past trading sessions: Mallinckrodt PLC, Akorn Inc., Pacira Pharmaceuticals Inc., and Rigel Pharmaceuticals Inc.. Staines-Upon-Thames, the UK headquartered Mallinckrodt PLC's shares jumped 11.11%, closing Thursday's trading ses
Dr. Erstad is currently a tenured professor and head of the Department of Pharmacy Practice& Science at the University of Arizona College of Pharmacy. Dr. Erstad has authored more than 200 peer-reviewed articles, monographs, and book chapters. This theme is reflected in many of my external service efforts, such as my work on the FDA Drug Safety and
South San Francisco, CA- Genentech, a member of the Roche Group, today announced that the U.S. Food and Drug Administration has approved Zelboraf for Erdheim-Chester disease with BRAF V600 mutation. 'This FDA decision means people living with Erdheim-Chester disease will now, for the first time, have an FDA- approved treatment option,' said Sandra
CURTIN, Australia, Nov. 10 The Pharmaceutical Society of Australia issued the following news release:. Today, Minister for Health Greg Hunt announced a partnership with the peak national body representing pharmacists, the Pharmaceutical Society of Australia. The Australian Digital Health Agency CEO Tim Kelsey said that 5.2 million Australians alr
BRIDGEWATER- Bausch+ Lomb, a leading global eye health company, today announced that it will feature three interactive exhibits during the Annual Meeting of the American Academy of Ophthalmology at the Ernest N. Morial Convention Center in New Orleans, LA, offering attendees the opportunity to gain hands-on experience with its latest innovations an
By a News Reporter-Staff News Editor at Drug Week As part of its comprehensive national plan to combat drug abuse, Walgreens is now stocking Narcan , an FDA- approved nasal form of naloxone, in all of its more than 8,000 pharmacies nationwide. "By stocking Narcan in all our pharmacies, we are making it easier for families and caregivers to hel
We are reporting net sales of $638,318 for the year ended June 30, 2017, which represents a 14.3% increase from the $558,524 reported in the comparable prior year. Gross profit for the year ended June 30, 2017 was $140,792 and our gross margin was 22.1% as compared to gross profit of $142,785 and gross margin of 25.6% in the comparable prior year.
COMPARED TO THE THREE AND SIX MONTHS ENDED SEPTEMBER 30, 2016 The following discussion of our financial condition and results of operations for the three six months ended September 30, 2017 and 2016 should be read in conjunction with our unaudited condensed consolidated financial statements and the notes to those statements that are included elsewh
The global dry eye syndrome drugs market is expected to grow at a CAGR of close to 8% during the forecast period, according to Technavio s latest market research. Emerging economies such as India, China, and Brazil are some of the most attractive countries for pharmaceutical companies globally. All these factors are expected to drive the mark
The following discussion and analysis, as well as other sections in this Quarterly Report on Form 10- Q, should be read in conjunction with the unaudited interim consolidated financial statements and related notes to the unaudited interim consolidated financial statements included elsewhere herein. Forward-looking statements involve a number of ris
Innovus Pharmaceuticals, Inc., an emerging commercial-stage pharmaceutical company that delivers safe, innovative and effective over-the-counter medicine and consumer care products to improve men s and women's health and respiratory diseases, today announced that it has entered into an agreement with ACON Laboratories, Inc.. ACON Labs is a San D
Medicare Part D members can now turn to Kmart Pharmacy as their 2018 preferred provider for pharmaceutical needs and receive substantial savings in their copays. That includes copays as low as $1 when they fill their prescriptions through a preferred network pharmacy such as Kmart Pharmacy. "Kmart Pharmacy prides itself on offering low-cost copa
Mesa Rx, a pharmaceutical cost savings consultancy, announced today the launch of their proprietary software solution that helps self-insured employers eliminate unnecessary drug spending. "We're protecting the interests of employers and their employees by making the purchase of drugs a more transparent and honest process," says Alex Schmelzer,
Eli Lilly and Company today announced new data showing that treatment with FORTEO for 24 months was associated with significantly fewer vertebral and clinical fractures compared with risedronate, a widely used oral bisphosphonate, in postmenopausal women with severe osteoporosis in the VERO clinical trial. Study results are published in the No
Basel- Novartis today announced that the company has submitted a Marketing Authorization Application to the European Medicines Agency for CTL019 for two indications. 'Since the historic FDA approval of Kymriah, formerly CTL019, we have launched, manufactured and supplied this highly individualized immunocelluar therapy in a commercial setting and t
CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS. This Quarterly Report on Form 10- Q contains forward-looking statements, within the meaning of Section 27 A of the Securities Act of 1933, as amended, and Section 21 E of the Securities Exchange Act of 1934, as amended, which reflect the Corporation's current estimates, expectations and...
Statements in this Quarterly Report that are not strictly historical are forward-looking statements and include statements about products in development, results and analyses of pre-clinical studies, clinical trials and studies, research and development expenses, cash expenditures, and alliances and partnerships, among other matters.
PLx Pharma Inc., a late-stage specialty pharmaceutical company focused on commercializing two patent-protected products, Aspertec? 325 mg and Aspertec? 81 mg, announced today its financial and certain operational results for the three- and nine-month periods ended September 30, 2017.. Net loss totaled $3.8 million, or per basic and diluted sh
-Sun BioPharma, Inc., a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of pancreatic diseases, announced today that it will implement the previously announced 1- for-10 reverse stock split. The reverse stock split will be effective as of the close of business on November 7, 2017 and the Company`s commo